The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Getahun, A.
Right arrow Articles by Heyman, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Getahun, A.
Right arrow Articles by Heyman, B.
The Journal of Immunology, 2004, 172: 5269-5276.
Copyright © 2004 by The American Association of Immunologists

IgG2a-Mediated Enhancement of Antibody and T Cell Responses and Its Relation to Inhibitory and Activating Fc{gamma} Receptors1

Andrew Getahun, Jörgen Dahlström, Sara Wernersson and Birgitta Heyman2

Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
A number of studies in experimental animal models point to an important role of Fc{gamma}Rs in autoimmunity and allergy. In this study, we investigate how the production of IgG, an early step in the chain of events leading to inflammation, is regulated by activating and inhibitory Fc{gamma}Rs. IgG Abs are known to feedback-enhance Ab responses to soluble Ags, and this effect requires activating Fc{gamma}Rs. To test proliferation of Th cells, mice were adoptively transferred with CD4+ T cells expressing a transgenic OVA-specific TCR before immunization with IgG2a anti-2,4,6-trinitrophenyl (TNP) plus OVA-TNP or with OVA-TNP alone. IgG2a induced a significant increase in OVA-specific T cell numbers, which preceded the OVA-specific Ab response and was dependent on the FcR{gamma} chain. The role of the inhibitory Fc{gamma}RIIB in Ab responses was studied in mice lacking this receptor. Although IgG2a enhanced primary Ab responses, development of germinal centers, and immunological memory in wild-type mice, enhancement was markedly stronger in Fc{gamma}RIIB–/– mice. The presented data are compatible with the hypothesis that the mechanism behind IgG2a-mediated up-regulation of Ab responses involves increased Ag presentation to CD4+ T cells by Fc{gamma}R+ APCs. Our observations also illustrate the intricate immunoregulatory role of IgG Abs. On the one hand, they enhance Ab responses via activating Fc{gamma}Rs, and on the other hand, they set an upper limit for the same Ab response via Fc{gamma}RIIB.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Immunoglobulin G-containing immune complexes (ICs)3 are capable of inducing inflammatory reactions, which, to a large extent, are mediated via a family of activating Fc{gamma}Rs (reviewed in Ref. 1). Fc{gamma}RI and Fc{gamma}RIII contain immunoreceptor tyrosine-based activation motifs (ITAM). Cross-linking of these receptors by their ligand, IgG/Ag complexes, induces intracellular signaling and various effector responses such as Ab-dependent cellular cytoxicity, mast cell degranulation, and phagocytosis (2). Fc{gamma}RIIB is an inhibitory receptor with an immunoreceptor tyrosine-based inhibition motif in the cytoplasmic tail. When Fc{gamma}RIIB is co-cross-linked with ITAM-containing receptors such as the B cell receptor (BCR), Fc{gamma}RI, Fc{gamma}RIII, and Fc{epsilon}RI, it inhibits ITAM-mediated signals (3). The in vivo role of Fc{gamma}Rs has been extensively studied in gene-targeted mice. Generally, inflammatory reactions, including models for autoimmune diseases, are exacerbated in mice lacking Fc{gamma}RIIB (Fc{gamma}RIIB–/–) and impaired in mice lacking functional activating Fc{gamma}RI and Fc{gamma}RIII (owing to deletion of the common FcR{gamma} chain, FcR{gamma}–/–) (4, 5).

The ligands for Fc{gamma}Rs, IgG Abs, obviously play a crucial role in initiating the effector functions of these receptors. IgG Abs are also potent regulators of the Ab-production per se. This takes place via a mechanism called Ab-mediated feedback regulation (6, 7). IgG, forming complexes in vivo with large particulate Ag, completely suppresses Ab responses to this Ag, a phenomenon that does not seem to require Fc{gamma}Rs (8, 9). IgG complexed to soluble protein Ags instead enhances the Ab response to this Ag by several hundredfold (10, 11, 12). Enhancement of Ab responses by the subclasses IgG1 and IgG2a requires the presence of activating Fc{gamma}Rs on a bone-marrow-derived cell type (11, 12) and, unlike enhancement by IgG3 (13), takes place in the absence of a functioning C system (14, 15). ICs containing IgG1 and IgG2a also bind to Fc{gamma}RIIB which, in addition to its inhibitory effects, can mediate endocytosis of IgG/Ag complexes by e.g., dendritic cells and therefore, hypothetically cause IgG-mediated enhancement. However, the observation (11) that IgG-mediated enhancement was impaired in FcR{gamma}–/– animals (expressing normal levels of Fc{gamma}RIIB) made it unlikely that Fc{gamma}RIIB is responsible for IgG-mediated enhancement. Attempting to directly confirm this conclusion in Fc{gamma}RIIB–/– mice, we noted that IgG1, IgG2a, and IgG2b could induce enhancement which was not only functional, but was markedly higher than in wild-type (WT) animals (11).

Given the central role of IgG/Ag complexes in immune responses, both in the early phases regulating Ab responses and in later phases as effector molecules inducing inflammatory reactions, we found it worthwhile to clarify how IgG2a up-regulates Ab-responses to soluble protein Ags. A working hypothesis was that IgG/Ag complexes are efficiently taken up by Fc{gamma}R+ APCs and presented to Th cells which then, via cognate help to B cells, induce augmented Ab responses. Using a transgenic system where the expansion of Ag-specific T cells could be monitored, we now visualize for the first time that IgG2a-mediated enhancement of Ab responses in vivo is indeed preceded by a FcR{gamma} chain-dependent proliferation of Ag-specific T cells. We have also confirmed and extended our previous analysis of the influence of Fc{gamma}RIIB on IgG2a-mediated feedback enhancement. The ability of IgG2a to enhance Ab responses, development of germinal centers (GCs), and immunological memory was much more pronounced in Fc{gamma}RIIB–/– mice than in WT controls. The difference in the magnitude of Ab-responses between the two strains was as big as 56-fold, thereby revealing one of the most potent down-regulatory effects of Fc{gamma}RIIB observed. Thus, IgG2a has a dual role in regulating immune responses to soluble Ags. Targeting Ag to activating FcR{gamma} chain-containing receptors enhances Ab as well as T cell responses while ligation of Fc{gamma}RIIB down-regulates enhancement.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

Mice carrying the H-2b haplotype have an I-Ab-linked low responsiveness to IgE/BSA-2,4,6-trinitrophenyl (TNP) and IgG/BSA-TNP complexes (16, 17). To achieve responder phenotypes, male Fc{gamma}RIIB-deficient mice (H-2b) (18), a gift from Dr J. V. Ravetch (Rockefeller University, New York, NY), were backcrossed to CBA/J mice (H-2k) (Bommice, Ry, Denmark) for 5 or 10 generations. Offspring from the 5th or 10th generation were intercrossed, and homozygous mutant H-2Ak animals were identified by PCR analysis of tail DNA. Offspring from these mice were used in the experiments. As WT controls for the 10th generation, CBA/J mice from Bommice were used. Mice homozygous for the WT Fc{gamma}RIIB alleles were selected from the intercrosses of the 5th-generation backcross and their offspring used as WT controls for 5th-generation mutant mice. PCRs to identify the H-2 haplotype (H-2k or H-2b) and Fc{gamma}RIIB genotype have been described (9).

In vivo T cell activation studies were performed on mice with a BALB/c background. As a source of OVA-specific T cells, DO11.10 mice, a gift from L. Westerberg (Karolinska Institute, Stockholm, Sweden) with the permission of Prof. K. Murphy (Washington University School of Medicine, St. Louis, MO), were used. DO11.10 mice carry a construct containing rearranged TCR{alpha} and TCR{beta} genes encoding a TCR specific for OVA 323-339 bound to I-Ad class II molecules (19), and have been backcrossed to BALB/c for >15 generations. Recipient mice were BALB/c (Bommice) and FcR{gamma}–/– (20) backcrossed to BALB/c for 12 generations (Taconic Farms, Germantown, NY). All animals were bred and maintained in the animal facilities at Department of Genetics and Pathology, Uppsala University (Uppsala, Sweden).

Antigens

OVA, BSA, keyhole limpet hemocyanin (KLH), and TNP were obtained from Sigma-Aldrich (St. Louis, MO). TNP in the form of picrylsulfonic acid hydrate (P-2297; Sigma-Aldrich) was conjugated to OVA and BSA in 0.28 M cacodylate buffer, pH 6.9, as described (21). After a 45- to 70-min incubation at room temperature, the reaction was stopped by an excess of glycyl-glycin (1 mg/ml; Merck, Darmstadt, Germany). Proteins were dialyzed against PBS, sterile-filtered, and stored at 4°C. The number of TNP residues per BSA or OVA was determined as described earlier (21). Conjugates with 12 TNP/BSA and 1.3 or 3 TNP/OVA (both yielding similar results) were used.

Antibodies

mAbs were derived from B cell hybridomas producing IgG2a anti-TNP (C4007B4, 7B4) (10) and IgE anti-TNP (IGELb4) (22). The hybridoma cell lines were cultured in DMEM with 5% FCS. IgG2a was purified on a protein A-Sepharose column (Amersham Pharmacia Biotech, Uppsala, Sweden) according to manufacturer’s recommendations. IgE was purified by affinity chromatography on a Sepharose column conjugated with monoclonal rat anti-mouse {kappa} (187.1.10) (23). Bound Ab was eluted with 0.1 M glycine-HCl buffer, pH 2.8. Abs were dialyzed against PBS, sterile-filtered, and stored at –20°C. Protein concentrations were determined by absorbance at 280 nm, assuming that an absorbance of 1.5 equals 1 mg/ml Ab. For flow cytometry, we used a PE-labeled IgG2a rat anti-mouse CD4 mAb (KH-CD4 or RM4–5; ImmunoKontact, Bioggio, Switzerland or BD PharMingen, San Diego, CA, respectively). The transgenic TCR was detected with a FITC-labeled murine IgG2a mAb specific for this particular TCR heterodimer (KJ1-26; Caltag Laboratories, Burlingame, CA) (24).

Immunizations

Mice were immunized in the tail veins with 0.2 ml of BSA-TNP or BSA-TNP/Ab complexes (and OVA as a specificity control) in PBS or with 0.1 ml of OVA-TNP or OVA-TNP/Ab complexes (and BSA or KLH as specificity controls) in PBS. The complexes were formed by incubating Ag with TNP-specific IgG2a or IgE mAbs for 1 h at 37°C immediately before immunization. For studies of the secondary response, mice were boosted with 20 µg of BSA in PBS s.c. in the flank.

Flow cytometry

Single cell suspensions from mouse spleens were prepared in ice-cold PBS by pressing cells through a mesh screen. RBCs were removed by hypotonic lysis, incubating spleen cells in 5 ml of ACK lysing buffer (0.15 M NH4Cl (Merck), 1.0 mM KHCO3 (Sigma-Aldrich), 0.1 mM Na2EDTA (Sigma-Aldrich), pH 7.3) for 5 min at room temperature. The spleen cells were washed twice in PBS, resuspended in 5 ml of PBS, and counted using a hemacytometer. Fluorescence staining was performed at 4°C in 100 µl of PBS containing 5 x 105 cells and predetermined optimal amounts of PE-labeled anti-CD4 (KH-CD4) and FITC-labeled anti-TCR (KJ1-26) mAbs. To reduce unspecific binding, 15 µl of normal BALB/c serum was added to the cell suspension before adding KJ1-26. After 30 min, the cells were washed twice with PBS containing 1% BSA (Sigma-Aldrich) and 0.1% NaN3 (Sigma-Aldrich). From each stained aliquot of cells, 40,000 events acquired by gating on all cells with the forward- and side-scatter properties of lymphocytes were collected on a FACSort flow cytometer (BD Biosciences, Mountain View, CA). Dead cells were excluded based on propidium iodide absorption. The collected data was analyzed using CellQuest version 3.3 software (BD Biosciences). DO11.10 T cells were identified as CD4+KJ1-26+ events. Absolute numbers of DO11.10 T cells were calculated by multiplying the percentage of CD4+KJ1-26+ events with the total number of live spleen cells.

Adoptive transfers

To study T cell activation in vivo, an adoptive transfer system developed in Dr. M. Jenkins’ group (25) was used. Spleen-cell suspensions from DO11.10 mice, containing 3 x 106 CD4+ KJ1-26+ cells, were adoptively transferred i.v. to BALB/c mice 1–2 days before immunization. In experiments where FcR{gamma}–/– (and their WT controls) were the recipients of DO11.10 cells (see Fig. 2), only CD4+ cells were transferred (to avoid "contamination" with Fc{gamma}R+ cells). CD4+ cells were prepared using Dynabeads Mouse CD4 (L3T4; Dynal Biotech, Oslo, Norway) and DETACHaBEAD Mouse CD4 (Dynal Biotech) according to manufacturer’s recommendations. Flow cytometry revealed that >99% of the cells were CD4+, and 2–2.5 x 106 CD4+KJ1-26+ cells were adoptively transferred i.v. to recipients.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 2. IgG2a-mediated enhancement of T cell proliferation is absent in FcR{gamma}–/– mice. WT BALB/c and FcR{gamma}–/– mice on BALB/c background were adoptively transferred with purified DO11.10 T cells (CD4+, >99%). Twenty-four hours later, recipients were immunized i.v. with 20 µg of OVA-TNP plus 20 µg of KLH (as a specificity control) alone, 20 µg of OVA-TNP plus 20 µg of KLH preincubated with 50 µg of IgG2a anti-TNP, or with 50 µg of IgG2a anti-TNP plus 20 µg of KLH alone. a, Four mice per group were sacrificed 3 days after immunization and the number of CD4+KJ126+ DO11.10 cells per spleen was determined by flow cytometry. b, Four mice per group were saved and bled on the indicated days. IgG anti-OVA-levels in sera were determined by ELISA (mean ± SEM). Immunization with 50 µg of IgG2a anti-TNP alone did not result in a T cell response nor an IgG anti-OVA response (data not shown). Asterisks indicate statistical differences between mice of the same strain given Ag alone and mice given Ab/Ag complexes. Asterisks within parentheses indicate the statistical differences between FcR{gamma}–/– and WT mice given Ab/Ag complexes. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Levels of IgG anti-KLH were not statistically higher in IgG2a/Ag-immunized than in Ag-immunized mice. A representative of four independent experiments is shown.

 
ELISA

Mice were bled from the tails and sera tested in ELISA for BSA-, OVA-, or KLH-specific IgG. Microtiter plates (Immunolon 2 HB; Dynex Technologies, Chantilly, VA) were coated overnight (o.n.) at 4°C with 100 µl OVA (10 µg/ml), BSA (50 µg/ml), or KLH (10 µg/ml) in PBS with 0.05% NaN3 (Bio-Rad, Richmond, CA). Fifty microliters of serial dilutions of serum samples in PBS-0.05% Tween 20 (PBS-Tw; Bio-Rad) was added to plates and incubated o.n. at 4°C. After washing, 50 µl of alkaline phosphatase-conjugated sheep anti-mouse IgG (Jackson ImmunoResearch Laboratories, West Grove, PA), diluted 1/1000 in PBS-Tw, was added and plates were incubated for 3 h at room temperature. After washing, 100 µl of substrate (p-nitro-phenylphosphate; Sigma-Aldrich) diluted in diethanolamine buffer was added and the absorbance at 405 nm was measured after 30 min incubation at room temperature. For BSA-specific ELISA, a polyclonal BSA-specific standard sera (affinity purified on BSA-Sepharose) with a starting concentration of 5.35 µg/ml was used. For OVA-specific ELISA, a polyclonal OVA-specific standard serum with a starting concentration of 3.47 µg/ml was used. Absorbance values at 405 nm were used to compare KLH-specific responses. Construction of standard curves and calculations were made by computer (Softmax; Molecular Devices, Menlo Park, CA). Stimulation indices (SI) were calculated as geometrical mean (anti-log10) of the experimental group divided by the geometrical mean of the control group.

ELISPOT assay

The number of B cells secreting BSA-specific IgG was determined using an ELISPOT assay (26). Spleens were removed and cell suspensions were prepared in DMEM with 0.5% normal mouse serum. One hundred-microliter cell suspensions were applied to BSA-coated microtiter plates (see ELISA) and incubated at 37°C, 5% CO2 for 3.5 h. Plates were washed and incubated at 4°C o.n. with 50 µl of alkaline phosphatase-conjugated sheep anti-mouse IgG diluted 1/100 in PBS-Tw. Spots were developed for 1 h at room temperature in 50 µl of 5-bromo-4-chloro-3-indolyl phosphate (Sigma-Aldrich) and counted under a stereomicroscope.

Immunohistochemistry

Spleens were removed and divided into three pieces. Each piece was mounted onto a cork plate with an embedding medium (Tissue-Tek OCT 4583 compound; Sakura Finetechnical, Tokyo, Japan) and frozen in isopropanol in liquid nitrogen. Six-micrometer cryosections were mounted onto a SuperFrost Plus microscope slide (Menzel-Gläser, Braunschweig, Germany). The sections were fixed in ice-cold acetone and rehydrated in PBS. GCs were stained with 10 µg/ml biotinylated peanutagglutinin (L-6135; Sigma-Aldrich). The bound biotinylated peanutagglutinin was detected using an ABComplex/HRP kit (DAKO, Glostrup, Denmark). GCs were counted "blindly" under a microscope in 15 sections taken from different parts of the spleen.

Delayed-type hypersensitivity

Mice were injected intradermally with 10 or 100 µg of BSA emulsified in CFA (Difco, Detroit, MI) at the root of the tail in a total volume of 50 µl. Seven days after primary immunization, mice were challenged with 10 µg of BSA in 10 µl of PBS in the right ear, or 10 µl of PBS alone in the left ear. Ear thickness was measured before, as well as 1, 2, 3, and 5 days after challenge with a micrometer, accurate to 0.01 mm (Oditest; Kroeplin, Schlüchtern, Germany). Ear swelling due to BSA-specific delayed-type hypersensitivity (DTH) is expressed as the micrometer swelling in the BSA-challenged ear subtracted from the micrometer swelling in the PBS-challenged ear.

Statistical analysis

Statistical differences between the control and the experimental groups were determined by Student’s t test: NS, p > 0.05; *, p < 0.05; **, p < 0.01; or ***, p < 0.001.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
IgG2a enhances proliferation of Ag-specific T cells in vivo

We first addressed the question of whether IgG2a/Ag complexes could induce detectable proliferation of Ag-specific Th cells in vivo. Transgenic OVA-specific DO11.10 CD4+ T cells were transferred to BALB/c mice. Recipients were immunized with OVA-TNP or preformed IgG2a anti-TNP/OVA-TNP complexes, and the number of OVA-specific T cells in the spleen was determined in flow cytometry (Fig. 1a). BALB/c mice transferred with DO11.10 cells but not immunized, or immunized with IgG2a anti-TNP alone, had small but detectable OVA-specific T cell populations (0.24 and 0.18%, respectively) which were absent in normal BALB/c mice (0.03%). Immunization with OVA-TNP increased the population to 0.36% and immunization with IgG2a anti-TNP/OVA-TNP complexes increased the population even further (1.56%). The 4.3-fold increase in population size after immunization with IgG2a-complexed Ag is representative; based on 12 independent experiments, the expansion ratios varied from 3.2- to 9.5-fold.



View larger version (50K):
[in this window]
[in a new window]
  		FIGURE 1. IgG2a enhances proliferation of Ag-specific CD4+ T cells as well as Ab responses. a, BALB/c mice were adoptively transferred with total spleen cells from DO11.10 transgenic mice containing 3 x 106 CD4+KJ1-26+ T cells. Twenty-four hours later, recipients (three mice per group) were left unimmunized or were immunized i.v. with 20 µg of OVA-TNP alone, 20 µg of OVA-TNP preincubated with 50 µg of IgG2a anti-TNP, or with 50 µg of IgG2a anti-TNP alone. As negative controls, normal BALB/c mice, neither transferred with DO11.10 cells nor immunized, were used. Mice were sacrificed 3 days after immunization and the percentage of CD4+ KJ1-26+ DO11.10 cells per spleen was determined by flow cytometry. A representative of five independent experiments is shown. b, BALB/c mice were adoptively transferred and immunized as in a plus 20 µg BSA (as a specificity control). On the indicated days, three mice per group were sacrificed and the number of CD4+ KJ1-26+ DO11.10 cells per spleen was determined by flow cytometry. Five mice per group were saved and serum levels of IgG anti-OVA was determined by ELISA (mean ± SEM). Immunization with 50 µg of IgG2a anti-TNP alone did not result in a T cell response nor an anti-OVA IgG response (data not shown). Asterisks indicate statistical differences between mice given Ag alone and mice given Ab/Ag complexes. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Levels of IgG anti-BSA were not statistically higher in IgG2a/Ag-immunized than in Ag-immunized mice. A representative of three independent experiments is shown.

 
The kinetics of the expansion of specific CD4+ T cells and the correlation to serum titers of OVA-specific IgG were then analyzed in the same system (Fig. 1b). As early as 2 days postimmunization, the number of OVA-specific T cells was significantly increased in mice immunized with IgG2a anti-TNP/OVA-TNP. The T cell response peaked at day 3, and the titers of OVA-specific IgG in serum around day 9. Thus, immunization of mice with IgG2a/Ag results in proliferation of specific CD4+ T cells, which precedes the enhanced Ab response.

IgG2a-mediated enhancement of T cell proliferation is absent in FcR{gamma}–/– mice

As mentioned, IgG2a-mediated enhancement of Ab responses is severely impaired in FcR{gamma}–/– mice (11). To examine whether the IgG2a-induced T cell expansion is FcR{gamma}-dependent, transgenic OVA-specific DO11.10 CD4+ T cells were transferred to WT and FcR{gamma}–/– mice. Recipients were immunized with OVA-TNP or preformed IgG2a anti-TNP/OVA-TNP complexes and the number of Ag-specific T cells in spleens was determined. Whereas T cell expansion was 5-fold in WT mice, no significant expansion of T cells was seen in FcR{gamma}–/– mice, neither in the experiment shown in Fig. 2a, nor in the three other experiments performed. Four mice per group were saved and bled at various time points, confirming that Fc{gamma}R–/– mice have significantly reduced Ab responses to IgG2a/Ag as compared with WT mice (Fig. 2b).

Enhanced IgG2a-mediated enhancement of primary Ab responses in Fc{gamma}RIIB–/– mice

To characterize the role of Fc{gamma}RIIB in regulating Ab responses, Fc{gamma}RIIB–/– and WT mice were immunized with preformed complexes of IgG2a anti-TNP/BSA-TNP or BSA-TNP alone, and the Ab response was analyzed. During the entire test period, Fc{gamma}RIIB–/– mice given IgG2a/Ag complexes had a much higher production of IgG anti-BSA than WT animals (Fig. 3a). The SI at the peak of the response (days 21 and 28) were 9.6 and 10.4 in WT animals, whereas the corresponding SI in Fc{gamma}RIIB–/– mice were 246 and 476. Thus, IgG2a caused an "enhanced enhancement" of the primary Ab response in the absence of the inhibitory Fc{gamma}RIIB.



View larger version (20K):
[in this window]
[in a new window]
  		FIGURE 3. Enhanced IgG2a-mediated enhancement of primary Ab responses in Fc{gamma}RIIB–/– mice. Groups of four to five WT CBA/J and Fc{gamma}RIIB–/– mice, backcrossed to CBA/J for five generations, were immunized i.v. with 50 µg of IgG2a anti-TNP plus 20 µg of BSA-TNP plus 20 µg of OVA (as a specificity control) or 20 µg of BSA-TNP plus 20 µg of OVA alone (a) or with 50 µg of IgE anti-TNP plus 20 µg of BSA-TNP plus 20 µg of OVA or 20 µg of BSA-TNP plus 20 µg of OVA alone (b). On the indicated days, mice were bled and IgG anti-BSA-levels in sera were measured by ELISA. Asterisks indicate statistical differences between mice of the same strain given Ag alone and mice given Ab/Ag complexes. Asterisks within parentheses indicate the statistical differences between Fc{gamma}RIIB–/– and WT mice given Ab/Ag complexes. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Levels of IgG anti-OVA were not statistically higher in IgG/Ag- or IgE/Ag-immunized than in Ag-immunized mice (data not shown).

 
To confirm that only the presence of the ligand for Fc{gamma}RIIB, IgG, in an IC would influence the Ab response, control mice were immunized with complexes of IgE anti-TNP/BSA-TNP or with BSA-TNP alone. IgE-mediated enhancement of Ab responses is dependent on the low affinity receptor for IgE (Fc{epsilon}RII, CD23) (27, 28), which does not contain an ITAM, and therefore is not expected to be down-regulated by Fc{gamma}RIIB. In line with this, there was no difference at any time point between the responses of Fc{gamma}RIIB–/– and WT mice to immunization with IgE/Ag-complexes (Fig. 3b).

Enhanced IgG2a-mediated priming for secondary Ab responses in Fc{gamma}RIIB–/– mice

To investigate the effect of Fc{gamma}RIIB on immunological memory, mice were primed with IgG2a anti-TNP/BSA-TNP i.v. and boosted with one s.c. injection of 20 µg of BSA in PBS 64 days later. Although secondary (as well as primary) Ab responses were markedly enhanced by IgG2a in WT mice, the effect was much more dramatic in Fc{gamma}RIIB–/– mice (Fig. 4).



View larger version (27K):
[in this window]
[in a new window]
  		FIGURE 4. Enhanced IgG2a-mediated priming for secondary Ab responses in Fc{gamma}RIIB–/–mice. Groups of five WT CBA/J and Fc{gamma}RIIB–/– mice, backcrossed to CBA for 10 generations, were primed i.v. with 50 µg of IgG2a anti-TNP plus 20 µg of BSA-TNP plus 20 µg of OVA (as a specificity control) or 20 µg of BSA-TNP plus 20 µg of OVA alone. All mice were boosted s.c. with 20 µg of BSA alone in PBS 64 days after primary immunization. On the indicated days, mice were bled and IgG anti-BSA-levels in sera were measured by ELISA. In mice of both strains primed with Ag alone, the levels of BSA-specific IgG were <0.9 µg/ml after primary injection and <1.8 µg/ml after booster injection (data not shown). Asterisks indicate statistical differences between mice of the same strain given Ag alone and mice given Ab/Ag complexes. Asterisks within parentheses indicate the statistical differences between Fc{gamma}RIIB–/– and WT mice given Ab/Ag complexes. *, p < 0.05; **, p < 0.01; ***, p < 0.001. Levels of IgG anti-OVA were not statistically higher in IgG/Ag-immunized than Ag-immunized mice (data not shown).

 
Higher numbers of B cells producing specific IgG in Fc{gamma}RIIB–/– mice

The augmented serum IgG response in Fc{gamma}RIIB–/– mice could be due to increased affinity, decreased clearance of IgG, increased number of specific Ab-producing B cells, or to a combination of these factors. To investigate whether the number of specific Ab-producing B cells differed between Fc{gamma}RIIB–/– and WT mice, both strains were immunized with IgG2a anti-TNP/BSA-TNP and their spleens were analyzed in an ELISPOT assay (Fig. 5). In Fc{gamma}RIIB–/– mice, B cells producing BSA-specific IgG were found already at day 6 with a peak at day 14 (3576 spots per spleen). The response was sustained at least until day 22 when the experiment was terminated. WT mice had fewer BSA-specific IgG-producing B cells over the entire observation period, with a maximal number (435 spots per spleen) 10 days after immunization. Sera from the mice analyzed in ELISPOT assays were also analyzed in ELISA, confirming that the levels of IgG anti-BSA were higher in Fc{gamma}RIIB–/– than in WT mice (data not shown).



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 5. Enhanced IgG2a-mediated induction of single Ag-specific B cells in Fc{gamma}RIIB–/– mice. WT CBA/J and Fc{gamma}RIIB–/– mice, backcrossed to CBA/J for five generations, were immunized i.v. with 50 µg of IgG2a anti-TNP plus 20 µg of BSA-TNP plus 20 µg of OVA (as a specificity control) or 20 µg of BSA-TNP plus 20 µg of OVA alone. On the indicated days, three Fc{gamma}RIIB–/– and three WT mice were sacrificed and the number of specific IgG-producing B cells was analyzed in a BSA-specific ELISPOT assay. Sera were also collected at each time point and IgG anti-BSA and anti-OVA titers were measured by ELISA (data not shown). *, p < 0.05; **, p < 0.01; ***, p < 0.001. Numbers of IgG anti-OVA-specific ELISPOTs were not statistically higher in mice immunized with IgG/Ag than in control mice (data not shown). A representative of three independent experiments is shown.

 
Earlier onset of GC formation in Fc{gamma}RIIB–/– mice

Next, we examined whether the elevated numbers of specific IgG-producing B cells in Fc{gamma}RIIB–/– mice were reflected in an increased GC formation. Spleens from Fc{gamma}RIIB–/– and WT mice were removed 3, 7, 10, and 14 days after immunization with IgG2a/BSA-TNP-complexes. Cryosections were stained with peanut hemagglutinin and 15 nonconsecutive sections of each spleen were examined (Table I). Three days after immunization, only a few GCs were detected in the two strains. Seven days after immunization, there were almost three times as many GCs in Fc{gamma}RIIB–/– mice as in WT mice. With time, however, the difference in GC numbers between WT and Fc{gamma}RIIB–/– mice appeared to even out, although the Ab response in the latter remained higher.


View this table:
[in this window]
[in a new window]
  		Table I. GC formation in Fc{gamma}RIIB–/– and WT micea

 
No difference in DTH between Fc{gamma}RIIB–/– and WT mice

DTH is a cell-mediated inflammatory response induced by primed Th1 cells (29). Mice lacking either Abs (µMT) or activating Fc{gamma}Rs (FcR{gamma}–/–) have a reduced ability to mount DTH reactions (30), suggesting that IgG formed during priming with Ag in CFA, is important for initiating DTH responses. We reasoned that this experimental system could be used to investigate whether Fc{gamma}RIIB negatively regulates the FcR{gamma}-dependent T cell priming required for a DTH reaction. Fc{gamma}RIIB–/– and WT mice were immunized with BSA in CFA and challenged with soluble BSA. Subsequent measuring of ear swelling demonstrated that both strains developed similar DTH reactions (Fig. 6, a and b). Interestingly, Fc{gamma}RIIB–/– mice given the highest dose of BSA had a higher IgG anti-BSA response than WT mice, although this was not mirrored in an enhanced DTH reaction (Fig. 6a).



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 6. Normal DTH responses in Fc{gamma}RIIB–/– mice. Groups of 8–11 WT CBA/J and Fc{gamma}RIIB–/– mice, backcrossed to CBA/J for 10 generations, were immunized with 100 µg (a) or 10 µg (b) of BSA in CFA. Seven days after primary immunizations, mice were challenged with BSA in the right ear and PBS, as a control, in the left ear. Ear thickness was measured immediately before, as well as 24, 48, 72, and 120 h after challenge and BSA-specific ear swelling was calculated. Sera were collected 7 days after challenge and the levels of BSA-specific IgG were determined in ELISA. The level of BSA-specific IgG in normal mouse serum was 0.27 µg/ml (data not shown). Asterisks indicate statistical differences between mice of the same strain challenged with BSA and mice challenged with PBS. Asterisks within parentheses indicate the statistical differences between the Fc{gamma}RIIB–/– and WT mice challenged with BSA. A representative of two independent experiments is shown. *, p < 0.05; **, p < 0.01; ***, p < 0.001.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
We have studied the involvement of Fc{gamma}Rs in B and T cell responses to IgG2a/Ag complexes in vivo. The fact that IgG2a can ligate both activating and inhibitory Fc{gamma}Rs is clearly reflected in the response to IgG2a/Ag complexes. Our main findings are that IgG2a, complexed to its specific Ag, induces 1) a potent FcR{gamma} chain-dependent proliferation of Ag-specific Th cells and 2) very high primary and secondary Ab responses in mice lacking the inhibitory Fc{gamma}RIIB.

The molecular mechanism behind the ability of IgG2a to enhance Ab responses via Fc{gamma}Rs has been postulated to be increased uptake of IgG2a/Ag complexes by Fc{gamma}R+ APCs, followed by efficient presentation of Ag to CD4+ Th cells. The ability of IgG to potentiate Ag presentation has been demonstrated in vitro (31, 32, 33, 34, 35) and ex vivo (34, 35), and has been implied in vivo (30, 36, 37). Here, we are able to directly visualize in vivo that IgG2a-mediated feedback enhancement of Ab responses to OVA is preceded by a rapid expansion of specific CD4+ T cells. The impairment of both T cell expansion and enhancement of Ab responses in FcR{gamma}–/– animals show that these functions are dependent on the presence of activating Fc{gamma}Rs. It is remarkable that i.v. immunization with rather low doses of native OVA (20 µg per mouse), complexed to IgG2a but without administration of conventional adjuvants, gives rise to a robust proliferation of T cells specific for one single OVA-peptide. We observed a 3.2- to 9.5-fold expansion of the splenic Ag-specific T cell population in mice immunized with IgG2a/Ag compared with mice immunized with Ag alone. Using the same adoptive transfer system, other workers observed a similar magnitude of T cell expansion in lymph nodes of mice immunized s.c. with native OVA together with LPS (38). However, to reach these levels of T cell proliferation, very high doses of Ag (2 mg per mouse) were required. Our results support the idea that IgG2a enhances Ab responses by increasing uptake of Ag by Fc{gamma}R+ APCs, leading to enhanced presentation of Ag to Th cells, which provide help to specific B cells. The observations also suggest that capture of Ag by IgG2a is an extremely efficient way to induce immune responses when the concentration of Ag is limited and no adjuvants are present, as could be expected during biological immune responses.

Fc{gamma}RIIB–/– mice are more susceptible to autoimmune diseases such as Goodpasture’s syndrome (39), collagen-induced arthritis (40, 41), and lupus (42) than WT animals, and also have augmented IgG-mediated anaphylactic (18) and Arthus (43) reactions. Only a limited number of reports are available on the role of Fc{gamma}RIIB in regulating Ab responses, i.e., the afferent limb of the inflammatory response. Fc{gamma}RIIB–/– mice immunized with SRBC or with KLH-TNP in adjuvant, produced ~5-fold higher amounts of Abs compared with WT mice (18). The difference in Ab production was not evident until after ~1 wk, probably reflecting the fact that endogenous IgG must first be produced to ligate Fc{gamma}RIIB. Administration of preformed IgG/Ag complexes is a shortcut to studying the regulatory effects of Fc{gamma}RIIB on Ab responses, without having to wait for endogenous IgG production. Using this approach, we have characterized a striking hyperresponsiveness to IgG-containing ICs in Fc{gamma}RIIB–/– mice. Although IgG2a caused enhancement of the primary Ab response, the priming for a secondary Ab response, the number of specific IgG-producing B cells, and the induction of GCs in WT mice, the responses were higher in Fc{gamma}RIIB–/– mice. As an example, we observed a 56-fold higher primary Ab response to IgG-complexed protein Ags than in WT mice, which is the most pronounced effect of Fc{gamma}RIIB on Ab responses reported so far. Interestingly, Fc{gamma}RIIB seems to negatively regulate Ab production by setting the upper level for Ab production rather than by completely preventing it. This is evidenced by the fact that IgG does indeed enhance Ab responses in WT animals although Fc{gamma}RIIB is present (Refs. 10 and 11 ; Figs. 3a and 4).

There are several hypothetical pathways by which Fc{gamma}RIIB can negatively regulate responses to IgG/Ag complexes. On the level of T cell priming, it may inhibit Fc{gamma}RI-mediated uptake of IgG/Ag or inhibit IC-induced dendritic cell maturation (34, 44, 45). FcR{gamma}–/– mice have reduced DTH responses and Th cell proliferation, most likely due to impaired IgG-mediated Ag presentation (30). The fact that Fc{gamma}RIIB does not inhibit DTH responses (Fig. 6) therefore argues against the idea that this receptor down-regulates responses to IgG2a/Ag complexes by inhibiting Ag presentation. In a similar system as the one described in Fig. 2, we have tested directly whether Fc{gamma}RIIB influences T cell priming. Fc{gamma}RIIB–/– mice on a BALB/c background were transferred with OVA-specific transgenic T cells from DO11.10 mice and immunized with OVA-TNP or IgG2a/OVA-TNP-complexes. In two of the experiments, we found no significant difference in T cell proliferation, whereas in two experiments, a 2-fold higher T cell proliferation in Fc{gamma}RIIB–/– mice was detected. Although this suggested that no major differences existed, interpretation of the data was complicated by our finding that Ab responses after immunization with IgG2a/OVA-TNP were only 3-fold higher in Fc{gamma}RIIB–/– mice on a BALB/c background than in WT animals. The reason for the less dramatic impact of Fc{gamma}RIIB on Ab responses in BALB/c mice compared with CBA/J mice is not known. Noteworthy is that while lack of Fc{gamma}RIIB in C57BL/6 mice led to spontaneous autoimmune disease, as well as to production of anti-nuclear Abs, no signs of autoimmunity were seen in BALB/c mice lacking the same receptor (42), again implying that Fc{gamma}RIIB in BALB/c mice plays a less significant inhibitory role on Ab responses than it does in other mouse strains.

Another hypothesis is that Fc{gamma}RIIB negatively regulates B cells when IgG2a/Ag complexes co-cross-link the BCR and Fc{gamma}RIIB. In vitro, this leads to inhibition of B cell signaling (46, 47, 48, 49), B cell apoptosis (50), and inhibition of BCR-mediated Ag uptake and presentation (51, 52). Support for the existence of Fc{gamma}RIIB-mediated inhibition of B cell activation in vivo comes from studies in different mouse strains, showing a correlation between reduced levels of Fc{gamma}RIIB expression on GC B cells (as a result of Fc{gamma}RIIB promoter polymorphisms) and higher Ab responses (53, 54). To date, there are no reports demonstrating that Fc{gamma}RIIB negatively regulates Ag-presentation via activating Fc{gamma}Rs. Our present finding that DTH reactions take place normally in Fc{gamma}RIIB–/– animals as well as recent data from Dr. T. Takai’s laboratory (55) argue against an influence of Fc{gamma}RIIB on Fc{gamma}R-mediated Ag-presentation. Additionally, an abundance of data (mentioned above) show that Fc{gamma}RIIB does indeed negatively regulate B cells. Therefore, we favor the idea that Fc{gamma}RIIB inhibits Ab responses to IgG-complexed Ag by coligating the BCR. To definitely prove this point, studies in conditional knockout mice, selectively lacking Fc{gamma}RIIB on B cells, will probably be required.

The presented data illustrates the intricate immunoregulatory role of IgG Abs. They enhance Ab responses via activating Fc{gamma}Rs, and in contrast, they down-regulate the same Ab response via Fc{gamma}RIIB. The net result is seen in WT mice as enhanced responses to IgG-complexed soluble Ags. The effect of the positive regulation alone is seen in Fc{gamma}RIIB–/– mice as extremely high responses to IgG-complexed soluble Ags. The balance between IgG-mediated up- and down-regulatory effects is most likely a delicate one and it is easy to envisage how perturbations may lead to autoimmune disease, reported to occur with increased frequency in Fc{gamma}RIIB–/– mice (39, 40, 41, 42).


   Acknowledgments
 
We thank I. Brogren for skilful technical assistance, Dr. S. Kleinau for critical reading of the manuscript, Dr. J. V. Ravetch for the gift of the Fc{gamma}RIIB–/– founder animals, Drs. K. Murphy and L. Westerberg for DO11.10 founders, Dr. M. Wabl for IgE, and Dr. P. Coulie for IgG hybridomas.


   Footnotes
 
1 This work was supported by The Swedish Research Council, Agnes och Mac Rudberg Foundation; Ellen, Walter, and Lennart Hesselman Foundation; Hans von Kantzow Foundation; King Gustaf V 80 Years Foundation; The Swedish Foundation for Health Care Science and Allergy Research; Ollie and Elof Ericsson Foundation; The Swedish Society for Medical Research; and the Network for Inflammation Research funded by the Swedish Foundation for Strategic Research. Back

2 Address correspondence and reprint requests to Dr. Birgitta Heyman, Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, SE-751 85 Uppsala, Sweden. E-mail address: birgitta.heyman{at}genpat.uu.se Back

3 Abbreviations used in this paper: IC, immune complex; ITAM, immunoreceptor tyrosine-based activation motif; BCR, B cell receptor; WT, wild type; GC, germinal center; TNP, 2,4,6-trinitrophenyl; o.n., overnight; KLH, keyhole limpet hemocyanin; DTH, delayed-type hypersensitivity; SI, stimulation index. Back

Received for publication December 4, 2003. Accepted for publication February 23, 2004.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Ravetch, J. V., R. A. Clynes. 1998. Divergent roles for Fc receptors and complement in vivo. Annu. Rev. Immunol. 16:421.[Medline]
  2. Gessner, J. E., H. Heiken, A. Tamm, R. E. Schmidt. 1998. The IgG Fc receptor family. Ann. Hematol. 76:231.[Medline]
  3. Vivier, E., M. Daëron. 1997. Immunoreceptor tyrosine-based inhibition motifs. Immunol. Today 18:286.[Medline]
  4. Takai, T.. 2002. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2:580.[Medline]
  5. Kleinau, S.. 2003. The impact of Fc receptors on the development of autoimmune diseases. Curr. Pharm. Des. 9:1861.[Medline]
  6. Heyman, B.. 2000. Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu. Rev. Immunol. 18:709.[Medline]
  7. Heyman, B.. 2003. Feedback regulation by IgG antibodies. Immunol. Lett. 88:157.[Medline]
  8. Karlsson, M. C., S. Wernersson, T. Diaz de Ståhl, S. Gustavsson, B. Heyman. 1999. Efficient IgG-mediated suppression of primary antibody responses in Fc{gamma} receptor-deficient mice. Proc. Natl. Acad. Sci. USA 96:2244.[Abstract/Free Full Text]
  9. Karlsson, M. C., A. Getahun, B. Heyman. 2001. Fc{gamma}RIIB in IgG-mediated suppression of antibody responses: different impact in vivo and in vitro. J. Immunol. 167:5558.[Abstract/Free Full Text]
  10. Coulie, P. G., J. Van Snick. 1985. Enhancement of IgG anti-carrier responses by IgG2 anti-hapten antibodies in mice. Eur. J. Immunol. 15:793.[Medline]
  11. Wernersson, S., M. C. Karlsson, J. Dahlström, R. Mattsson, J. S. Verbeek, B. Heyman. 1999. IgG-mediated enhancement of antibody responses is low in Fc receptor {gamma} chain-deficient mice and increased in Fc{gamma}RII-deficient mice. J. Immunol. 163:618.[Abstract/Free Full Text]
  12. Diaz de Ståhl, T., B. Heyman. 2001. IgG2a-mediated enhancement of antibody responses is dependent on FcR{gamma}+ bone marrow-derived cells. Scand. J. Immunol. 54:495.[Medline]
  13. Diaz de Ståhl, T., J. Dahlström, M. C. Carroll, B. Heyman. 2003. A role for complement in feedback-enhancement of antibody responses by IgG3. J. Exp. Med. 197:1183.[Abstract/Free Full Text]
  14. Wiersma, E. J., M. Nose, B. Heyman. 1990. Evidence of IgG-mediated enhancement of the antibody response in vivo without complement activation via the classical pathway. Eur. J. Immunol. 20:2585.[Medline]
  15. Applequist, S. E., J. Dahlström, N. Jiang, H. Molina, B. Heyman. 2000. Antibody production in mice deficient for complement receptors 1 and 2 can be induced by IgG/Ag and IgE/Ag, but not IgM/Ag complexes. J. Immunol. 165:2398.[Abstract/Free Full Text]
  16. Gustavsson, S., S. Hjulström-Chomez, B. M. Lidström, N. Ahlborg, R. Andersson, B. Heyman. 1998. Impaired antibody responses in H-2Ab mice. J. Immunol. 161:1765.[Abstract/Free Full Text]
  17. Gustavsson, S., S. Chomez, B. Heyman. 1999. Low responsiveness to immunization with immunoglobulin E/antigen and immunoglobulin G/antigen complexes in H-2Ab mice. Scand. J. Immunol. 50:45.[Medline]
  18. Takai, T., M. Ono, M. Hikida, H. Ohmori, J. V. Ravetch. 1996. Augmented humoral and anaphylactic responses in Fc{gamma}RII-deficient mice. Nature 379:346.[Medline]
  19. Murphy, K. M., A. B. Heimberger, D. Y. Loh. 1990. Induction by antigen of intrathymic apoptosis of CD4+CD8+TCRlow thymocytes in vivo. Science 250:1720.[Abstract/Free Full Text]
  20. Takai, T., M. Li, D. Sylvestre, R. Clynes, J. V. Ravetch. 1994. FcR{gamma} chain deletion results in pleiotrophic effector cell defects. Cell 76:519.[Medline]
  21. Good, A. H. L., C. Wofsy, C. Henry, J. Kimura. 1980. Preparation of hapten-modified protein antigens. B. B. Mishell, and S. M. Shiigi, eds. Selected Methods in Cellular Immunology 343. W. H. Freeman and Company, San Francisco.
  22. Rudolph, A. K., P. D. Burrows, M. R. Wabl. 1981. Thirteen hybridomas secreting hapten-specific immunoglobulin E from mice with Iga or Igb heavy chain haplotype. Eur. J. Immunol. 11:527.[Medline]
  23. Ware, C. F., J. L. Reade, L. C. Der. 1984. A rat anti-mouse {kappa} chain specific monoclonal antibody, 187.1.10: purification, immunochemical properties and its utility as a general second-antibody reagent. J. Immunol. Methods. 74:93.[Medline]
  24. Haskins, K., R. Kubo, J. White, M. Pigeon, J. Kappler, P. Marrack. 1983. The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J. Exp. Med. 157:1149.[Abstract/Free Full Text]
  25. Kearney, E. R., K. A. Pape, D. Y. Loh, M. K. Jenkins. 1994. Visualization of peptide-specific T cell immunity and peripheral tolerance induction in vivo. Immunity 1:327.[Medline]
  26. Westman, S., S. Gustavsson, B. Heyman. 1997. Early expansion of secondary B cells after primary immunization with antigen complexed with IgE. Scand. J. Immunol. 46:10.[Medline]
  27. Fujiwara, H., H. Kikutani, S. Suematsu, T. Naka, K. Yoshida, T. Tanaka, M. Suemura, N. Matsumoto, S. Kojima, T. Kishimoto, N. Yoshida. 1994. The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice. Proc. Natl. Acad. Sci. USA 91:6835.[Abstract/Free Full Text]
  28. Gustavsson, S., S. Wernersson, B. Heyman. 2000. Restoration of the antibody response to IgE/antigen complexes in CD23- deficient mice by CD23+ spleen or bone marrow cells. J. Immunol. 164:3990.[Abstract/Free Full Text]
  29. Cher, D. J., T. R. Mosmann. 1987. Two types of murine helper T cell clones. II. Delayed-type hypersensitivity is mediated by TH1 clones. J. Immunol. 138:3688.[Abstract]
  30. Hamano, Y., H. Arase, H. Saisho, T. Saito. 2000. Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J. Immunol. 164:6113.[Abstract/Free Full Text]
  31. Manca, F., D. Fenoglio, G. Li Pira, A. Kunkl, F. Celada. 1991. Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies. J. Exp. Med. 173:37.[Abstract/Free Full Text]
  32. Barnes, N., A. L. Gavin, P. S. Tan, P. Mottram, F. Koentgen, P. M. Hogarth. 2002. Fc{gamma}RI-deficient mice show multiple alterations to inflammatory and immune responses. Immunity 16:379.[Medline]
  33. Serre, K., P. Machy, J. C. Grivel, G. Jolly, N. Brun, J. Barbet, L. Leserman. 1998. Efficient presentation of multivalent antigens targeted to various cell surface molecules of dendritic cells and surface Ig of antigen-specific B cells. J. Immunol. 161:6059.[Abstract/Free Full Text]
  34. Rafiq, K., A. Bergtold, R. Clynes. 2002. Immune complex-mediated antigen presentation induces tumor immunity. J. Clin. Invest. 110:71.[Medline]
  35. Akiyama, K., S. Ebihara, A. Yada, K. Matsumura, S. Aiba, T. Nukiwa, T. Takai. 2003. Targeting apoptotic tumor cells to Fc{gamma}R provides efficient and versatile vaccination against tumors by dendritic cells. J. Immunol. 170:1641.[Abstract/Free Full Text]
  36. Heijnen, I. A., M. J. van Vugt, N. A. Fanger, R. F. Graziano, T. P. de Wit, F. M. Hofhuis, P. M. Guyre, P. J. Capel, J. S. Verbeek, J. G. van de Winkel. 1996. Antigen targeting to myeloid-specific human Fc{gamma}RI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97:331.[Medline]
  37. Merica, R., A. Khoruts, K. A. Pape, R. L. Reinhardt, M. K. Jenkins. 2000. Antigen-experienced CD4 T cells display a reduced capacity for clonal expansion in vivo that is imposed by factors present in the immune host. J. Immunol. 164:4551.[Abstract/Free Full Text]
  38. Pape, K. A., A. Khoruts, A. Mondino, M. K. Jenkins. 1997. Inflammatory cytokines enhance the in vivo clonal expansion and differentiation of antigen-activated CD4+ T cells. J. Immunol. 159:591.[Abstract]
  39. Nakamura, A., T. Yuasa, A. Ujike, M. Ono, T. Nukiwa, J. V. Ravetch, T. Takai. 2000. Fc{gamma} receptor IIB-deficient mice develop Goodpasture’s syndrome upon immunization with type IV collagen: a novel murine model for autoimmune glomerular basement membrane disease. J. Exp. Med. 191:899.[Abstract/Free Full Text]
  40. Yuasa, T., S. Kubo, T. Yoshino, A. Ujike, K. Matsumura, M. Ono, J. V. Ravetch, T. Takai. 1999. Deletion of Fc{gamma} receptor IIB renders H-2b mice susceptible to collagen-induced arthritis. J. Exp. Med. 189:187.[Abstract/Free Full Text]
  41. Kleinau, S., P. Martinsson, B. Heyman. 2000. Induction and suppression of collagen-induced arthritis is dependent on distinct Fc{gamma} receptors. J. Exp. Med. 191:1611.[Abstract/Free Full Text]
  42. Bolland, S., J. V. Ravetch. 2000. Spontaneous autoimmune disease in Fc{gamma}RIIB-deficient mice results from strain-specific epistasis. Immunity 13:277.[Medline]
  43. Clynes, R., J. S. Maizes, R. Guinamard, M. Ono, T. Takai, J. V. Ravetch. 1999. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189:179.[Abstract/Free Full Text]
  44. Regnault, A., D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery, M. Rescigno, T. Saito, S. Verbeek, C. Bonnerot, P. Ricciardi-Castagnoli, S. Amigorena. 1999. Fc{gamma} receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189:371.[Abstract/Free Full Text]
  45. Kalergis, A. M., J. V. Ravetch. 2002. Inducing tumor immunity through the selective engagement of activating Fc{gamma} receptors on dendritic cells. J. Exp. Med. 195:1653.[Abstract/Free Full Text]
  46. Bijsterbosch, M. K., G. G. Klaus. 1985. Crosslinking of surface immunoglobulin and Fc receptors on B lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors. J. Exp. Med. 162:1825.[Abstract/Free Full Text]
  47. Choquet, D., M. Partiseti, S. Amigorena, C. Bonnerot, W. H. Fridman, H. Korn. 1993. Cross-linking of IgG receptors inhibits membrane immunoglobulin-stimulated calcium influx in B lymphocytes. J. Cell Biol. 121:355.[Abstract/Free Full Text]
  48. Muta, T., T. Kurosaki, Z. Misulovin, M. Sanchez, M. C. Nussenzweig, J. V. Ravetch. 1994. A 13-amino-acid motif in the cytoplasmic domain of Fc{gamma}RIIB modulates B-cell receptor signalling. Nature 369:340.[Medline]
  49. Nakamura, K., J. C. Cambier. 1998. B cell antigen receptor (BCR)-mediated formation of a SHP-2-pp120 complex and its inhibition by Fc{gamma}RIIB1-BCR coligation. J. Immunol. 161:684.[Abstract/Free Full Text]
  50. Ashman, R. F., D. Peckham, L. L. Stunz. 1996. Fc receptor off-signal in the B cell involves apoptosis. J. Immunol. 157:5.[Abstract]
  51. Minskoff, S. A., K. Matter, I. Mellman. 1998. Fc{gamma}RII-B1 regulates the presentation of B cell receptor-bound antigens. J. Immunol. 161:2079.[Abstract/Free Full Text]
  52. Wagle, N. M., A. E. Faassen, J. H. Kim, S. K. Pierce. 1999. Regulation of B cell receptor-mediated MHC class II antigen processing by Fc{gamma}RIIB1. J. Immunol. 162:2732.[Abstract/Free Full Text]
  53. Jiang, Y., S. Hirose, M. Abe, R. Sanokawa-Akakura, M. Ohtsuji, X. Mi, N. Li, Y. Xiu, D. Zhang, J. Shirai, et al 2000. Polymorphisms in IgG Fc receptor IIB regulatory regions associated with autoimmune susceptibility. Immunogenetics 51:429.[Medline]
  54. Xiu, Y., K. Nakamura, M. Abe, N. Li, X. S. Wen, Y. Jiang, D. Zhang, H. Tsurui, S. Matsuoka, Y. Hamano, et al 2002. Transcriptional regulation of Fcgr2b gene by polymorphic promoter region and its contribution to humoral immune responses. J. Immunol. 169:4340.[Abstract/Free Full Text]
  55. Yada, A., S. Ebihara, K. Matsumura, S. Endo, T. Maeda, A. Nakamura, K. Akiyama, S. Aiba, T. Takai. 2003. Accelerated antigen presentation and elicitation of humoral response in vivo by Fc{gamma}RIIB- and Fc{gamma}RI/III-mediated immune complex uptake. Cell. Immunol. 225:21.[Medline]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
F. Hjelm, M. C. I. Karlsson, and B. Heyman
A Novel B Cell-Mediated Transport of IgE-Immune Complexes to the Follicle of the Spleen
J. Immunol., May 15, 2008; 180(10): 6604 - 6610.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. B. Rawool, C. Bitsaktsis, Y. Li, D. R. Gosselin, Y. Lin, N. V. Kurkure, D. W. Metzger, and E. J. Gosselin
Utilization of Fc Receptors as a Mucosal Vaccine Strategy against an Intracellular Bacterium, Francisella tularensis
J. Immunol., April 15, 2008; 180(8): 5548 - 5557.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al.
Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Clin. Cancer Res., September 1, 2007; 13(17): 5133 - 5143.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. D. Desai, S. O. Harbers, M. Flores, L. Colonna, M. P. Downie, A. Bergtold, S. Jung, and R. Clynes
Fc{gamma} Receptor IIB on Dendritic Cells Enforces Peripheral Tolerance by Inhibiting Effector T Cell Responses
J. Immunol., May 15, 2007; 178(10): 6217 - 6226.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. H. Schuurhuis, N. van Montfoort, A. Ioan-Facsinay, R. Jiawan, M. Camps, J. Nouta, C. J. M. Melief, J. S. Verbeek, and F. Ossendorp
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.
J. Immunol., April 15, 2006; 176(8): 4573 - 4580.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
L. J. Brady
Antibody-Mediated Immunomodulation: a Strategy To Improve Host Responses against Microbial Antigens
Infect. Immun., February 1, 2005; 73(2): 671 - 678.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow